Adaptive Biotechnologies Corporation

NASDAQ:ADPT

Biotechnology

Healthcare
$28.46 +3.66%

+$0.61 today

Market cap
$4.61B
Beta
2.15
P/E (TTM)
-54.5
EPS (TTM)
-$0.32
52W Low $9.96High $20.76

Volume 2.21M

Average 1.94M

ADPT Short-term Debt

Borrowings and the current portion of long-term debt due within one year.

Adaptive Biotechnologies CorporationNASDAQ: ADPT

Short-term Debt · Q2 FY2026 · quarter ended Jun 2026

Short-term debt remains negative

Q2 FY2026 short-term debt was $8.82M, compared with $0 a year earlier.

Context

  • Short-term debt amounted to 1.4% of total assets at the end of Q2 FY2026, up 1.4 pp from a year earlier.
  • Short-term debt increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$8.82M-38.4% QoQ
Last fiscal yearDec 2025
$13.56M— YoY
Year agoJun 2025
$0— since
Short-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Short-term Debt history

USD · from the balance sheet

Latest · FY2025
13.56M USD
Year-over-year change
—

Short-term Debt vs competitors

How ADPT compares with its peers on the latest reported figures

  • ADPT's Jun 2026 short-term debt of $8.82M is the 3rd highest of the 10 companies compared; the peer median is $0.
  • Short-term debt amounts to 1.4% of total assets for ADPT, versus a peer median of 0.0%.
ADPT Competitors Peer median
Short-term Debt for ADPT and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ZLABZai Lab LimitedJun 2026$238.1M +36.4%—22.2%
LEGNLegend Biotech CorporationSep 2026$44.1M -69.1%—2.6%
ADPTAdaptive Biotechnologies CorporationJun 2026$8.82M ——1.4%
CPRXCatalyst Pharmaceuticals, Inc.Mar 2026$446K ——0.0%
IDYAIDEAYA Biosciences, Inc.Mar 2026$350K ——0.0%
SRRKScholar Rock Holding CorporationSep 2026$0 -100.0%—0.0%
TARSTarsus Pharmaceuticals, Inc.Sep 2026$0 -100.0%—0.0%
IRONDisc Medicine, Inc.Sep 2026$0 ——0.0%
BEAMBeam Therapeutics Inc.Jun 2026$0 ——0.0%
MLYSMineralys Therapeutics, Inc.Jun 2026$0 ——0.0%
Peer median (excluding ADPT) $0-84.6%—0.0%

Competitors are the stored peer set for ADPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents139.07M90.03M65.06M47.92M70.5M
Short-term Investments214M408.17M281.34M174.37M156.49M
Net Receivables17.41M40.06M37.97M41.73M50.37M
Inventory19.26M14.45M14.45M8.44M9.82M
Other Current Assets09.44M11.37M11.29M13.02M
Total Current Assets402.75M562.15M410.19M283.75M300.19M
Property, Plant & Equipment (Net)172.94M164.21M120.32M94.38M74.72M
Goodwill118.97M118.97M118.97M118.97M118.97M
Intangible Assets8.53M6.83M5.13M3.43M1.73M
Long-term Investments217.15M0033.66M15.92M
Tax Assets00000
Other Non-current Assets3.01M4.46M6.52M5.18M1.21M
Total Non-current Assets520.6M294.47M250.95M255.62M212.55M
Total Assets923.34M856.62M661.13M539.38M512.74M
Account Payables3.31M8.08M7.72M7.27M6.47M
Short-term Debt000013.56M
Tax Payables391K194K59K176K0
Deferred Revenue80.46M64.12M48.63M55.69M45.19M
Other Current Liabilities15.64M15.94M13.69M16.7M7.7M
Total Current Liabilities113.81M109.79M88.02M98.05M89.92M
Long-term Debt0000196.79M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)98.75M58.6M44.79M27.26M1.01M
Other Non-current Liabilities0125.36M130.66M132.43M(70.21M)
Total Non-current Liabilities205.44M282.73M264.84M238.84M197.82M
Total Liabilities319.24M392.52M352.86M336.89M287.74M
Common Stock14K14K14K14K15K
Retained Earnings(718.89M)(919.08M)(1.14B)(1.3B)(1.36B)
Accumulated OCI(1.14M)(4.12M)215K166K253K
Other Stockholders Equity00000
Minority Interest110K(67K)(121K)(224K)6.21M
Total Equity604.1M464.1M308.28M202.49M225M
Total Debt111.74M108M98.77M89.39M280.58M
Net Debt(27.33M)17.97M33.71M41.47M210.09M

Adaptive Biotechnologies Corporation

NASDAQ:ADPT

Intrinsic Alpha fair value

Locked

Current Price

$28.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.